Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-07-02
DOI
10.1002/ejhf.2289
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies
- (2021) Shirley Xu et al. Frontiers in Cardiovascular Medicine
- The Next Decade of Immune Checkpoint Therapy
- (2021) Padmanee Sharma et al. Cancer Discovery
- Heart-Specific Immune Responses in an Animal Model of AutoimmuneRelated Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation
- (2020) Mariella Bockstahler et al. CIRCULATION
- Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
- (2020) Joerg Herrmann Nature Reviews Cardiology
- The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
- (2020) Rossana Franzin et al. Frontiers in Immunology
- Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
- (2019) Yi-Long Wu et al. Journal of Thoracic Oncology
- Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis
- (2019) John George et al. PANCREATOLOGY
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
- (2019) Makoto Ueno et al. Lancet Gastroenterology & Hepatology
- Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
- (2019) Ahmad A. Tarhini et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure and Optimization of Checkpoint Inhibitors
- (2019) Sarah L. Picardo et al. Cancers
- Cardiotoxicities Associated with Immune Checkpoint Inhibitors
- (2018) Shu Yang et al. CURRENT PROBLEMS IN CANCER
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Takotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors
- (2018) Stephane Ederhy et al. JACC-Cardiovascular Imaging
- Immune checkpoint inhibitors and cardiovascular toxicity
- (2018) Alexander R Lyon et al. LANCET ONCOLOGY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- PubTerm: a web tool for organizing, annotating and curating genes, diseases, molecules and other concepts from PubMed records
- (2018) José Garcia-Pelaez et al. Database-The Journal of Biological Databases and Curation
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease
- (2017) Kathryn W. Juchem et al. JOURNAL OF IMMUNOLOGY
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
- (2017) Michele Maio et al. LANCET ONCOLOGY
- Interstitial lung disease induced by fluoxetine: Systematic review of literature and analysis of Vigiaccess, Eudravigilance and a national pharmacovigilance database
- (2017) Arianna Deidda et al. PHARMACOLOGICAL RESEARCH
- Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study
- (2016) S. Kanda et al. ANNALS OF ONCOLOGY
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- (2016) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression
- (2016) Saby George et al. JAMA Oncology
- Meta-analysis in clinical trials revisited
- (2015) Rebecca DerSimonian et al. Contemporary Clinical Trials
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice
- (2014) J. A. Lucas et al. JOURNAL OF IMMUNOLOGY
- PD-1 deficiency results in the development of fatal myocarditis in MRL mice
- (2010) Jian Wang et al. INTERNATIONAL IMMUNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started